论文部分内容阅读
伤寒在现今世界许多地区仍然是一严重的公共卫生问题。注射伤寒菌苗虽有保护作用,但常有发热、头痛及局部发炎等副作用。作者采用一种新的口服减毒活菌苗——伤寒杆菌Ty2/a变异株,在埃及作了为期三年(1978——1981)并没有安慰剂对照的现场试验。菌苗:Ty2/a菌苗株作为减毒活菌苗曾在志愿者中进行评价,口服5～8剂菌苗(相当3～10×10~10活菌)无明显副作用;攻击试验菌苗保护率为87%,而未免疫的对照组伤寒发病率达53%。作者所
Typhoid fever is still a serious public health problem in many parts of the world today. Although the injection of typhoid bacilli protective effect, but often fever, headache and local inflammation and other side effects. The authors used a new oral attenuated live vaccine - typhoid typhi Ty2 / a mutant strain in Egypt for a three-year (1978-1981) and no placebo-controlled field trials. Vaccines: The Ty2 / a vaccine strain was evaluated as a live attenuated vaccine in volunteers with no apparent side effects of 5 to 8 doses of vaccine (equivalent to 3 to 10 x 10 to 10 viable cells); challenge test vaccine The protection rate was 87%, while the un-immunized control group had a 53% incidence of typhoid fever. Author of